GleamWall
中文EN

ALT Altimmune, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1326190 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY105.0%
TTM net income YoY7.3%
TTM EPS YoY25.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-230,461.0%
Net margin-214,861.0%
FCF margin—
EBITDA margin-230,187.8%

Returns

ROE-50.6%
ROA-42.0%
ROIC (approx.)-49.4%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets19.7%
Debt / equity0.15x
Current ratio18.55x
Interest coverage-57.76x

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-9.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$41,000$20,000
R&D expense$66.43M$82.23M
SG&A expense$28.10M$20.97M
Operating income-$94.49M-$103.17M
Interest expense$1.64M$9,000
Pretax income-$88.77M-$95.06M
Income tax-$681,000—
Net income-$88.09M-$95.06M
EBITDA-$94.38M-$102.93M
EPS (basic)-1.00-1.34
EPS (diluted)-1.00-1.34
Weighted avg. shares (diluted)88.10M71.00M
Balance sheet
Cash & equivalents$43.76M$36.97M
Short-term investments$229.70M$94.97M
Current assets$278.19M$137.25M
PP&E, net$312,000$413,000
Intangibles—$0
Total assets$279.93M$139.31M
Current liabilities$15.00M$10.47M
Long-term debt$34.29M—
Total debt$34.29M—
Total liabilities$55.04M$15.80M
Shareholders' equity$224.89M$123.51M
Net debt-$9.47M—
Shares outstanding110.88M72.35M
Cash flow statement
Operating cash flow-$67.53M-$79.85M
Capital expenditure$11,000—
Free cash flow-$67.55M—
Investing cash flow-$132.47M-$28.39M
Financing cash flow$206.84M$10.04M
Depreciation & amortization$112,000$238,000
Stock-based compensation$16.08M$14.39M

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.